Document is current
Any future updates will be listed below
-
Authors
Taipale, Heidi
Rahman, Syed https://orcid.org/0000-0002-4006-3327
Tanskanen, Antti
Mehtälä, Juha
Hoti, Fabian
Jedenius, Erik
Enkusson, Dana
Leval, Amy
Sermon, Jan
Tiihonen, Jari https://orcid.org/0000-0002-0400-6798
Mittendorfer-Rutz, Ellenor
- License Information
-
More Information
Article History
Received: 30 May 2019
Accepted: 10 January 2020
First Online: 27 January 2020
Competing interests
: J. Tiihonen reports serving as a consultant to the Finnish Medicines Agency Fimea, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen-Cilag, Lundbeck, and Organon; receiving fees for giving expert testimonies to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka and Pfizer; receiving lecture fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Novartis, Otsuka, Pfizer; receiving grants from Stanley Foundation and the Sigrid Jusélius Foundation; serving as a member of the advisory boards for AstraZeneca, Eli Lilly, Janssen-Cilag, and Otsuka, and participating in research projects funded by Janssen-Cilag and Eli Lilly with grants paid to Karolinska Institutet. F. Hoti and J. Mehtälä reported being employed by EPID Research, which is a contract research organization that performs commissioned pharmacoepidemiological studies, and thus its employees have been and currently are working in collaboration with several pharmaceutical companies. A. Tanskanen, E.Mittendorfer-Rutz, S. Rahman and H. Taipale reported participating in research projects funded by Janssen-Cilag, and A. Tanskanen and H. Taipale participating in research projects funded by Eli Lilly, with grants paid to the employer institution. A. Tanskanen reported serving as a member of advisory board for Janssen-Cilag. E. Jedenius, D. Enkusson, A. Leval, and J. Sermon are employed by Janssen Cilag Pharmaceuticals.
